Acrivon Therapeutics, Inc. Common Stock
Healthcare

NASDAQ:ACRV · NASDAQ Global Market

Market Cap $54.28M Beta 1.91 P/E (TTM) -0.8
$1.72 +3.16%

+$0.05 today

52W Low $1.15High $3.56

Vol 0.26M · Avg 0.60M

EPS (TTM) -$2.00Biotechnology

Dividends

Measure the reliability of shareholder income

Look beyond the current yield by checking payout history, cash support, buybacks, and other ways management returns capital to owners.

Dividend analysis for Acrivon Therapeutics, Inc. Common Stock should look at more than the latest yield. Review ACRV payout history, free cash flow support, buybacks, balance sheet flexibility, and peer income metrics together so the shareholder return profile is judged by durability, not by a single headline percentage that may change with price movement.

Dividends

Dividend history, growth & yield

Dividends

Yield

0.00%

Annual Div/Share

$0.00

Payout Ratio

0.0%

Frequency

Shareholder Yield

0.00%

Next Ex-Date

Not announced

Next Payment

Analysis

The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

Dividend Yield (TTM)

0.00%

Buyback Yield (TTM)

0.00%

Debt Paydown (TTM)

0.00%

Total Yield (TTM)

0.00%

Showing limited history. Sign in for more

Analysis

Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.

Competitor Dividends

Peer payout, dividend, and buyback comparison

No competitor dividend data available.

Does ACRV stock pay dividends?

Acrivon Therapeutics, Inc. Common Stock (ACRV) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.

Is ACRV's dividend covered?

The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.

Explore More

Continue the stock analysis

Jump to another research area for this company.